ArticleIn vivo (Athens, Greece)

Platinum-free Interval May Predict Duration of Maintenance Bevacizumab and Survival in Platinum-sensitive Recurrent Ovarian Cancer.

Soo Hyun Oh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.